Last reviewed · How we verify

Placebo plus metformin IR — Competitive Intelligence Brief

Placebo plus metformin IR (Placebo plus metformin IR) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Biguanide. Area: Diabetes.

phase 3 Biguanide AMP-activated protein kinase (AMPK); mitochondrial glycerophosphate dehydrogenase Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

Placebo plus metformin IR (Placebo plus metformin IR) — AstraZeneca. Metformin reduces hepatic glucose production and improves insulin sensitivity, while placebo serves as a control comparator in this combination study.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Placebo plus metformin IR TARGET Placebo plus metformin IR AstraZeneca phase 3 Biguanide AMP-activated protein kinase (AMPK); mitochondrial glycerophosphate dehydrogenase
metformin + glimepiride metformin + glimepiride GlaxoSmithKline marketed Antidiabetic combination (biguanide + sulfonylurea) Metformin: mitochondrial glycerophosphate dehydrogenase; Glimepiride: ATP-sensitive potassium channel (KATP)
Metformin Small Pack Metformin Small Pack GlaxoSmithKline marketed Biguanide AMP-activated protein kinase (AMPK); complex I of the mitochondrial electron transport chain
Metformin cloridrate Metformin cloridrate University Magna Graecia marketed Biguanide AMP-activated protein kinase (AMPK)
Detemir insulin, Aspart insulin, Metformin Detemir insulin, Aspart insulin, Metformin University Hospital, Toulouse marketed Insulin combination with biguanide Insulin receptor (detemir and aspart); AMPK and mitochondrial glycerophosphate dehydrogenase (metformin)
Metformin / alogliptin Oral Product Metformin / alogliptin Oral Product University of Catanzaro marketed Biguanide / DPP-4 inhibitor combination Metformin: mitochondrial glycerophosphate dehydrogenase; Alogliptin: dipeptidyl peptidase-4 (DPP-4)
MET + Glibenclamide Group MET + Glibenclamide Group Hospital de Clinicas de Porto Alegre marketed Antidiabetic combination (biguanide + sulfonylurea) AMPK pathway (metformin); ATP-sensitive potassium channel (glibenclamide)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Biguanide class)

  1. AstraZeneca · 4 drugs in this class
  2. Merck Sharp & Dohme LLC · 3 drugs in this class
  3. University of Texas Southwestern Medical Center · 2 drugs in this class
  4. Mount Sinai Hospital, Canada · 2 drugs in this class
  5. GlaxoSmithKline · 2 drugs in this class
  6. Eli Lilly and Company · 2 drugs in this class
  7. University Magna Graecia · 2 drugs in this class
  8. First Affiliated Hospital of Wenzhou Medical University · 1 drug in this class
  9. Ente Ospedaliero Ospedali Galliera · 1 drug in this class
  10. Daewoong Pharmaceutical Co. LTD. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Placebo plus metformin IR — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-plus-metformin-ir. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: